Our STN: BL 125703/361

SUPPLEMENT APPROVAL
April 12, 2024

Kite Pharma, Inc.
Attention: Alissa Lee
2400 Broadway
Santa Monica, CA 90404

Dear Ms. Lee:

We have approved your request submitted and received February 16, 2024, to supplement your Biologics License Application (BLA) submitted under section 351(a) of the Public Health Service Act for brexucabtagene autoleucel (TECARTUS) to update the following sections of the package insert to include new safety information on the risk of T cell malignancies s following BCMA- and CD19-directed genetically modified autologous T cell immunotherapies: Boxed Warning, Warnings and Precautions, Postmarketing Experience, Patient Counseling Information and Medication Guide.

The review of this supplement was associated with our January 23, 2024, SAFETY LABELING CHANGE NOTIFICATION LETTER, notifying you, under Section 505(o)(4) of the Federal Food, Drug, and Cosmetic Act (FDCA), of new safety information that we determined should be included in the labeling for brexucabtagene autoleucel (TECARTUS). This information pertains to the risk of T cell malignancies, with serious outcomes, including hospitalization and death, following treatment with BCMA- and CD19-directed genetically modified autologous T cell immunotherapies.

LABELING

We hereby approve the draft content of labeling Package Insert and Medication Guide submitted on April 12, 2024.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, please submit the final content of labeling (21 CFR 601.14) in Structured Product Labeling (SPL) format via the FDA automated drug registration and listing system, (eLIST) as described at http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm. Content of labeling must be identical to the Package Insert, Patient Package Insert, Instructions for Use, and Medication Guide] submitted on April 8, 2024. Information on submitting SPL files using eLIST may be found in the guidance for industry *SPL Standard for Content of Labeling Technical Qs and As* at http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf.

The SPL will be accessible via publicly available labeling repositories.

All final labeling should be submitted as Product Correspondence to this BLA, STN BL 125703 at the time of use and include implementation information on Form FDA 356h.

ADVERTISING AND PROMOTIONAL LABELING

You may submit two draft copies of the proposed introductory advertising and promotional labeling with Form FDA 2253 to the Advertising and Promotional Labeling Branch at the following address:

Food and Drug Administration
Center for Biologics Evaluation and Research
Document Control Center
10903 New Hampshire Ave.
WO71–G112
Silver Spring, MD 20993-0002

You must submit copies of your final advertising and promotional labeling at the time of initial dissemination or publication, accompanied by Form FDA 2253 (21 CFR 601.12(f)(4)).

All promotional claims must be consistent with and not contrary to approved labeling. You should not make a comparative promotional claim or claim of superiority over other products unless you have substantial evidence or substantial clinical experience to support such claims (21 CFR 202.1(e)(6)).

Please submit an amendment to all pending supplemental applications for this BLA that include revised labeling incorporating a revised content of labeling that includes these changes.

We will include information contained in the above-referenced supplement in your BLA file.

Sincerely,

Nicole Verdun, MD
Director
Office of Therapeutic Products
Center for Biologics Evaluation and Research